Navigation Links
AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
Date:10/15/2009

REDWOOD CITY, Calif., Oct. 15 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. announced today that results of its Phase 1 studies evaluating the pharmacokinetics of its oral transmucosal NanoTab(TM) formulation of sufentanil will be featured in two oral presentations at the upcoming American Society of Anesthesiologists Annual Meeting in New Orleans. Dr. Pamela Palmer, Chief Medical Officer of AcelRx, will present in the following sessions. Abstracts are available through the American Society of Anesthesiologists web site.

    Tuesday, October 20, 2009
    Oral Session - Chronic & Cancer Pain
    8:00 am, Room 355
    Abstract 1040
    "Pharmacokinetics and Dose Proportionality of Sublingual Sufentanil
    NanoTab in Healthy Volunteers"

    Tuesday, October 20, 2009
    Oral Session - Regional Anesthesia & Acute Pain
    1:00 pm, Room 355
    Abstract 1222
    "Single- and Repeat-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab
    in Healthy Volunteers"

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals is a privately held pharmaceutical company dedicated to the development and commercialization of new therapies for the treatment of pain and other conditions where there is an unmet need for improved safety and efficacy. The company applies its proprietary NanoTab dosage form and delivery technologies to enhance the safety, therapeutic benefit and commercial attractiveness of currently approved compounds. For additional information about AcelRx Pharmaceuticals visit http://www.acelrx.com.

SOURCE AcelRx Pharmaceuticals, Inc.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
5. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
6. Raptor Pharmaceuticals Provides Update of Product Programs
7. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
8. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
9. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
10. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
11. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 Many patients don,t realize that they ... a pharmacy just a few blocks away charges only ... problem Medicationdiscountcard.com has created a price comparison ... much their medication will cost at most nearby pharmacies. ... Medicationdiscountcard.com takes all of the ...
(Date:1/19/2017)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... consumables for the medical and veterinary markets worldwide, has ... for the third quarter fiscal year 2017, ended December ... ET on Thursday, January 26, 2017.  The Company will ... 2017 after the market closes on Thursday, January 26, ...
(Date:1/19/2017)... 19, 2017   Science Exchange , the leading ... that the first five replication studies from the ... published in eLife today. Despite intense scrutiny around ... practical evaluation of reproducibility rates that may identify ... other assessments of reproducibility, the results of this ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated ... met with big-name retail buyers at the January ECRM Trade Show in Hilton Head, ... the utmost safety standards in all of its creations to help create a more ...
(Date:1/21/2017)... ... ... Salveo for life, a company that distributes an effervescent lime-flavored drink called ... part of its presence to expand its market reach. , Using a formula developed ... nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, whilst supporting ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Dianne Travis-Teague, the electrifying line-up of events for its annual meeting “Coming Home ... and community. “Coming Home 2017” will be held on Friday January 27 ...
(Date:1/21/2017)... ... January 21, 2017 , ... The Nobel ... Dan Holtzclaw in media for its creos™ line of bone regenerative products. ... Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a variety of ...
(Date:1/20/2017)... ... 20, 2017 , ... Source Vitál Apothecary, a skin and body care company ... the company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports ... work in the nutritional, sports and health industries a chance to meet in private ...
Breaking Medicine News(10 mins):